The Clostridium difficile Infection – Daily Symptoms (CDI-DaySyms™) Patient-Reported Outcome (PRO) Questionnaire: Final Validation and Responder Thresholds

Abstract

1284. The Clostridium difficile Infection – Daily Symptoms (CDI-DaySymsTM) Patient-Reported Outcome (PRO) Questionnaire: Final Validation and Responder Thresholds George H. Talbot, MD, FIDSA; Leah Kleinman, Dr PH; Evan W. Davies, MSc; Elke Hunsche, PhD; Laurie Roberts, MPH and Carl Erik Nord, MD, PhD, FIDSA; Talbot Advisors LLC, Anna Maria, Florida, Outcomes Research, Evidera, Bethesda, Maryland, Global Market Access & Pricing, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

Cite this paper

@inproceedings{Talbot2017TheCD, title={The Clostridium difficile Infection – Daily Symptoms (CDI-DaySyms™) Patient-Reported Outcome (PRO) Questionnaire: Final Validation and Responder Thresholds}, author={George Harrison Talbot and Leah Kleinman and Evan W. Davies and Elke Hunsche and Laurie J Roberts and Carl Erik Nord}, year={2017} }